Overview


According to FutureWise analysis the market for Antiplatelet in 2023 is US$ 3.97 billion, and is expected to reach US$ 5.61 billion by 2031 at a CAGR of 4.42%.

Antiplatelets are a class of medications that prevent platelets from sticking together and developing blood clots. Platelets are small cells in the blood that clump together to form clots, which can be essential for stopping bleeding after an injury. However, in certain situations, such as in the heart or brain arteries, clots can form and block blood flow, leading to severe medical conditions like heart attacks or strokes. Antiplatelet drugs interrupt with the process of platelet aggregation, making it more challenging to stick together and form clots. They are commonly prescribed to individuals at risk of cardiovascular events, particularly those with conditions such as coronary artery disease, atrial fibrillation, or a history of strokes or heart attacks. The first well-known antiplatelet drug is aspirin. It is a cyclooxygenase inhibitor. 

Other common antiplatelet medications include clopidogrel, ticagrelor, and prasugrel, which are also widely used. Clopidogrel is commonly prescribed to individuals who have had a recent heart attack stroke or have certain types of chest pain (angina). It works by blocking a specific receptor on the surface of platelets, preventing them from sticking together and forming clots. Ticagrelor is another antiplatelet drug used to prevent blood clots in individuals with acute coronary syndrome (ACS) or a past record of heart attack. It works by blocking another receptor on platelets, effectively preventing them from aggregating. Prasugrel is mostly used in individuals who have undergone a procedure to open up blocked arteries (like angioplasty) or those who have had a heart attack. It acts similarly to clopidogrel but is more powerful and acts more quickly.

FutureWise Market Research has published a report that provides an insightful analysis antiplatelet market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts antiplatelet market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Abbott Laboratories
  • Armetheon Inc
  • AstraZeneca
  • Bayer AG
  • Daiichi Sankyo Co.
  • Eli Lilly
  • F. Hoffmann-La Roche AG
  • Genetech
  • Glaxosmithkline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Antiplatelet Market:

  • In Feb 2021, Sanofi announced the approval of additional indication for Plavix (Clopidogrel) by the European Commission. This new indication includes using a combination of Plavix and aspirin for patients with minor ischemic stroke and high-risk Transient Ischemia Attack within one day of the above events. Under this novel indication, the usage can be continued for 21 days and, subsequently, long-term antiplatelet therapy.

The increasing prevalence of cardiovascular conditions, such as heart attacks, strokes, and peripheral artery disease, may be attributed to a convergence of modern lifestyle factors. Sedentary habits, characterized by prolonged periods of physical inactivity, have become increasingly dominant in today's society, leading to a rise in cardiovascular health issues. Also, diets rich in processed foods, excessive sugars, and unhealthy fats have become unremarkable, contributing significantly to the rise in heart-related diseases. Moreover, the advancements in healthcare technology have ushered in a new era of accuracy and efficacy in treating cardiovascular conditions. Breakthroughs in diagnostic techniques, including advanced imaging techniques and sophisticated biomarker analysis, allow for more precise and convenient identification of individuals at risk of thrombotic events. Further, the development of innovative drug delivery systems has revolutionized the way antiplatelet medications are administered and absorbed in the body. Controlled-release formulations and targeted delivery mechanisms provide optimal dosing, improving the medication's effectiveness while minimizing potential side effects. However, the landscape of cardiovascular care is characterized by a dynamic interplay of various treatment options, and alternative approaches such as anticoagulants and interventional procedures may pose a potential challenge to the market growth of antiplatelet drugs. Anticoagulants, for instance, offer an alternative approach to managing thrombotic risks by inhibiting blood clotting factors. Anticoagulants are a competitive option for clinicians because of their efficacy and suitability for certain patient populations. Also, the bleeding complications associated with antiplatelet drugs, especially when administered in high doses or over long durations, are a significant constraint in their adoption. While these medications prevent harmful blood clots, the delicate balance between inhibiting clot formation and maintaining normal hemostasis might be disrupted. This increased risk of bleeding events may be a significant concern for certain patients, especially those with pre-existing bleeding disorders or undergoing surgical procedures. Therefore, hindering the growth of the market.

By Product Type

  • Aspirin
  • Clopidogrel
  • Prasugrel
  • Ticagrelor
  • Cangrelor
  • Abciximab
  • Others

By Mode of Administration

  • Oral
  • Intravenous

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. This is attributed to factors such as the increase in the prevalence of cardiovascular diseases such as stroke, coronary artery disease, and myocardial infarction (heart attack), the rise in adoption of antiplatelet drugs, research and development activities, sedentary lifestyle, and growing geriatric population drive the growth of the antiplatelet market in the region. Moreover, the presence of key players, increasing demand for diseases-specific treatment, increasing novel product launches, partnerships, and collaborations, and a rise in healthcare spending for cardiovascular diseases present new opportunities in the US and further boost the market growth over the projection period.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Antiplatelet Market By Product Type, By Mode of Administration, and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

 

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Antiplatelet Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Product Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antiplatelet Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Antiplatelet Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Product Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Product Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Antiplatelet Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Aspirin
        2. Clopidogrel
        3. Prasugrel
        4. Ticagrelor
        5. Cangrelor
        6. Abciximab
        7. Others

  • 8.   Antiplatelet Market, By Mode of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Intravenous

  • 9.   North America Antiplatelet Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Antiplatelet Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Antiplatelet Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Antiplatelet Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Antiplatelet Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Abbott Laboratories
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Armetheon Inc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. AstraZeneca
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Bayer AG
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Daiichi Sankyo Co.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Eli Lilly
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. F Hoffmann-La Roche AG
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Genetech
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Glaxosmithkline
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Johnson & Johnson
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Merck
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Novartis
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Pfizer Inc.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients